$GILD Recent Headlines Gilead says its drug gi
Post# of 94145
Posted On: 05/22/2014 10:22:35 AM
$GILD Recent Headlines
Gilead says its drug gives hepatitis C patients more cost-effective cure 5:06 p.m. April 30, 2014 - blogs.marketwatch.com
Why a diverse ETF portfolio is right for these times 6:29 a.m. April 30, 2014 - John Prestbo
Internet, biotech could spawn next Apple: Allianz CIO 7:12 a.m. April 29, 2014 - Barbara Kollmeyer
What Obamacare problems? Aetna results not showing any ill effects 12:34 p.m. April 24, 2014 - blogs.marketwatch.com
U.S. stocks tumble; S&P 500 ends 6-day run 4:46 p.m. April 23, 2014 - Anora Mahmudova
Apple, Facebook stuck in red ahead of earnings 3:02 p.m. April 23, 2014 - Saumya Vaishampayan
U.S. stock futures pause after six-session win streak 8:57 a.m. April 23, 2014 - Sara Sjolin
Game day for Facebook and Apple, volume 'signalling the nasty' 6:50 a.m. April 23, 2014 - blogs.marketwatch.com
Apple, Facebook, Boeing are stocks to watch 5:30 a.m. April 23, 2014 - Sue Chang
Gilead shares climb; AT&T, Amgen shares fall 5:55 p.m. April 22, 2014 - Myra P. Saefong
Gilead scores big on earnings with new drug, but investors getting wary 5:46 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead earnings buoyed by Hepatitis-C drug 5:04 p.m. April 22, 2014 - Anna Prior
Gilead Sciences shares up 4.5% in after-hours trade 4:35 p.m. April 22, 2014 - Myra P. Saefong
Gilead beats expectations; Sovaldi sales hit $2.3 bln 4:22 p.m. April 22, 2014 - Claudia Assis
Gilead: Hep C drug Sovaldi sells $2.27 billion 4:17 p.m. April 22, 2014 - Claudia Assis
Gilead Sciences Q1 non GAAP EPS $1.48 vs. 48c 4:15 p.m. April 22, 2014 - Claudia Assis
Should doctors care what treatments cost? 4:14 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead shares to resume trade at 4:30 Eastern 4:09 p.m. April 22, 2014 - Laura Mandaro
Gilead shares are halted 4:03 p.m. April 22, 2014 - Laura Mandaro
S&P 500, Nasdaq extend win streak to 6 sessions: Stock market live blog recap 3:56 p.m. April 22, 2014 - blogs.marketwatch.com
Chimerix, Inc. (CMRX) Gains: Stock Up 13.9% - Tale of the Tape 8:44 a.m. Today - Zacks.com
Two Biotechs Mastering Their Domains 8:08 a.m. Today - Barrons.com
Making The Call: Vertex's Cystic Fibrosis Trials Will Succeed. Here's Why. 7:00 a.m. Today - TheStreet.com
Despite Data Thefts, the Password Endures 10:25 p.m. May 21, 2014 - The Wall Street Journal Interactive Edition
Data on Novartis' Ultibro Breezhaler - Analyst Blog 6:30 p.m. May 21, 2014 - Zacks.com
Data on Novartis' Ultibro Breezhaler - Analyst Blog 6:30 p.m. May 21, 2014 - Zacks.com
Top 5 Hedge Fund Net Buys 5:24 p.m. May 21, 2014 - GuruFocus.com
Intercept Sinks on Cholesterol Issue - Analyst Blog 5:12 p.m. May 21, 2014 - Zacks.com
Additional Data on InterMune's Esbriet - Analyst Blog 5:05 p.m. May 21, 2014 - Zacks.com
Dendreon Up on Provenge Data - Analyst Blog 4:40 p.m. May 21, 2014 - Zacks.com
AbbVie's Humira Gets Orphan Drug Designation - Analyst Blog 4:30 p.m. May 21, 2014 - Zacks.com
Myriad Genetics Unveils Positive Prolaris Data - Analyst Blog 3:10 p.m. May 21, 2014 - Zacks.com
Gilead's GS-5806 Encourages - Analyst Blog 11:50 a.m. May 21, 2014 - Zacks.com
Celgene Inks Licensing Deal with AADi - Analyst Blog 11:30 a.m. May 21, 2014 - Zacks.com
Insmed (INSM) in Focus: Stock Moves 6.7% Higher - Tale of the Tape 9:18 a.m. May 21, 2014 - Zacks.com
Dendreon Corp. (DNDN) Catches Eye: Stock Up 8% - Tale of the Tape 8:44 a.m. May 21, 2014 - Zacks.com
Auspex Pharmaceuticals (ASPX) Jumps: Stock Rises 9.5% - Tale of the Tape 8:30 a.m. May 21, 2014 - Zacks.com
Invest In AbbVie's New Blockbuster Drug 7:35 a.m. May 21, 2014 - Seeking Alpha
U.S. insurers get indigestion from high drug prices 7:34 a.m. May 21, 2014 - Seeking Alpha
Gilead RSV drug succeeds in Phase 2 trial 6:48 p.m. May 20, 2014 - Seeking Alpha
Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults 5:00 p.m. May 20, 2014 - BusinessWire - BZX
Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology 7:40 a.m. May 20, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the 2014 UBS Healthcare Conference on Tuesday, May 20 5:00 p.m. May 19, 2014 - BusinessWire - BZX
Critical Alerts For Goldman Sachs, Noodles & Company, Starbucks, Gilead Sciences, and Time Warner Cable Released By InvestorsObserver 9:31 a.m. May 14, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14 5:00 p.m. May 13, 2014 - BusinessWire - BZX
Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 4:31 p.m. May 9, 2014 - BusinessWire - BZX
Cancer Diagnostics Partnering Terms and Agreements 5:41 p.m. May 7, 2014 - PR Newswire - PRF
Gilead Announces $5 Billion Share Repurchase Program 5:17 p.m. May 7, 2014 - BusinessWire - BZX
Medivir: a Supplemental New Drug Application Has Been Submitted to the U.S. FDA for Simeprevir in Combination with Sofosbuvir 8:06 a.m. May 7, 2014 - BusinessWire - BZX
Biotech Stocks Review -- Research on Retrophin, Merrimack, Gilead Sciences, and Rexahn Pharma 12:37 p.m. May 6, 2014 - PR Newswire - PRF
BetterInvesting Magazine Releases July Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use 4:15 p.m. May 2, 2014 - PR Newswire - PRF
Parion Sciences Reacquires Rights to Epithelial Sodium Channel Inhibitors 9:00 a.m. April 30, 2014 - PR Newswire - PRF
The World Market for Orphan Drugs 6:59 p.m. April 29, 2014 - PR Newswire - PRF
Critical Alerts For Comcast, Gilead Sciences, Ciena, Adobe Systems, and Celldex Therapeutics Released By InvestorsObserver 9:31 a.m. April 29, 2014 - PR Newswire - PRF
Federal Circuit Rules for Axinn Client Natco Pharma Ltd. in Tamiflu Patent Appeal 1:50 p.m. April 25, 2014 - BusinessWire - BZX
Stockholder Rights Plan, Quarterly Results, Clinical Trial Results, Purchase Agreements, and New Contracts - Analyst Notes on Allergan, Gilead, Pfizer, Actavis and Express Scripts 8:00 a.m. April 25, 2014 - PR Newswire - PRF
Gilead Sciences Announces First Quarter 2014 Financial Results 4:03 p.m. April 22, 2014 - BusinessWire - BZX
Gilead Sciences’ New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA 4:30 p.m. April 21, 2014 - BusinessWire - BZX
Young Scientists From Around the State Will Compete for Top Honors at the 63rd California State Science Fair 6:31 p.m. April 16, 2014 - PR Newswire - PRF
Gilead Sciences to Release First Quarter 2014 Financial Results on Tuesday, April 22, 2014 5:00 p.m. April 15, 2014 - BusinessWire - BZX
Gilead says its drug gives hepatitis C patients more cost-effective cure 5:06 p.m. April 30, 2014 - blogs.marketwatch.com
Why a diverse ETF portfolio is right for these times 6:29 a.m. April 30, 2014 - John Prestbo
Internet, biotech could spawn next Apple: Allianz CIO 7:12 a.m. April 29, 2014 - Barbara Kollmeyer
What Obamacare problems? Aetna results not showing any ill effects 12:34 p.m. April 24, 2014 - blogs.marketwatch.com
U.S. stocks tumble; S&P 500 ends 6-day run 4:46 p.m. April 23, 2014 - Anora Mahmudova
Apple, Facebook stuck in red ahead of earnings 3:02 p.m. April 23, 2014 - Saumya Vaishampayan
U.S. stock futures pause after six-session win streak 8:57 a.m. April 23, 2014 - Sara Sjolin
Game day for Facebook and Apple, volume 'signalling the nasty' 6:50 a.m. April 23, 2014 - blogs.marketwatch.com
Apple, Facebook, Boeing are stocks to watch 5:30 a.m. April 23, 2014 - Sue Chang
Gilead shares climb; AT&T, Amgen shares fall 5:55 p.m. April 22, 2014 - Myra P. Saefong
Gilead scores big on earnings with new drug, but investors getting wary 5:46 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead earnings buoyed by Hepatitis-C drug 5:04 p.m. April 22, 2014 - Anna Prior
Gilead Sciences shares up 4.5% in after-hours trade 4:35 p.m. April 22, 2014 - Myra P. Saefong
Gilead beats expectations; Sovaldi sales hit $2.3 bln 4:22 p.m. April 22, 2014 - Claudia Assis
Gilead: Hep C drug Sovaldi sells $2.27 billion 4:17 p.m. April 22, 2014 - Claudia Assis
Gilead Sciences Q1 non GAAP EPS $1.48 vs. 48c 4:15 p.m. April 22, 2014 - Claudia Assis
Should doctors care what treatments cost? 4:14 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead shares to resume trade at 4:30 Eastern 4:09 p.m. April 22, 2014 - Laura Mandaro
Gilead shares are halted 4:03 p.m. April 22, 2014 - Laura Mandaro
S&P 500, Nasdaq extend win streak to 6 sessions: Stock market live blog recap 3:56 p.m. April 22, 2014 - blogs.marketwatch.com
Chimerix, Inc. (CMRX) Gains: Stock Up 13.9% - Tale of the Tape 8:44 a.m. Today - Zacks.com
Two Biotechs Mastering Their Domains 8:08 a.m. Today - Barrons.com
Making The Call: Vertex's Cystic Fibrosis Trials Will Succeed. Here's Why. 7:00 a.m. Today - TheStreet.com
Despite Data Thefts, the Password Endures 10:25 p.m. May 21, 2014 - The Wall Street Journal Interactive Edition
Data on Novartis' Ultibro Breezhaler - Analyst Blog 6:30 p.m. May 21, 2014 - Zacks.com
Data on Novartis' Ultibro Breezhaler - Analyst Blog 6:30 p.m. May 21, 2014 - Zacks.com
Top 5 Hedge Fund Net Buys 5:24 p.m. May 21, 2014 - GuruFocus.com
Intercept Sinks on Cholesterol Issue - Analyst Blog 5:12 p.m. May 21, 2014 - Zacks.com
Additional Data on InterMune's Esbriet - Analyst Blog 5:05 p.m. May 21, 2014 - Zacks.com
Dendreon Up on Provenge Data - Analyst Blog 4:40 p.m. May 21, 2014 - Zacks.com
AbbVie's Humira Gets Orphan Drug Designation - Analyst Blog 4:30 p.m. May 21, 2014 - Zacks.com
Myriad Genetics Unveils Positive Prolaris Data - Analyst Blog 3:10 p.m. May 21, 2014 - Zacks.com
Gilead's GS-5806 Encourages - Analyst Blog 11:50 a.m. May 21, 2014 - Zacks.com
Celgene Inks Licensing Deal with AADi - Analyst Blog 11:30 a.m. May 21, 2014 - Zacks.com
Insmed (INSM) in Focus: Stock Moves 6.7% Higher - Tale of the Tape 9:18 a.m. May 21, 2014 - Zacks.com
Dendreon Corp. (DNDN) Catches Eye: Stock Up 8% - Tale of the Tape 8:44 a.m. May 21, 2014 - Zacks.com
Auspex Pharmaceuticals (ASPX) Jumps: Stock Rises 9.5% - Tale of the Tape 8:30 a.m. May 21, 2014 - Zacks.com
Invest In AbbVie's New Blockbuster Drug 7:35 a.m. May 21, 2014 - Seeking Alpha
U.S. insurers get indigestion from high drug prices 7:34 a.m. May 21, 2014 - Seeking Alpha
Gilead RSV drug succeeds in Phase 2 trial 6:48 p.m. May 20, 2014 - Seeking Alpha
Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults 5:00 p.m. May 20, 2014 - BusinessWire - BZX
Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology 7:40 a.m. May 20, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the 2014 UBS Healthcare Conference on Tuesday, May 20 5:00 p.m. May 19, 2014 - BusinessWire - BZX
Critical Alerts For Goldman Sachs, Noodles & Company, Starbucks, Gilead Sciences, and Time Warner Cable Released By InvestorsObserver 9:31 a.m. May 14, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14 5:00 p.m. May 13, 2014 - BusinessWire - BZX
Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 4:31 p.m. May 9, 2014 - BusinessWire - BZX
Cancer Diagnostics Partnering Terms and Agreements 5:41 p.m. May 7, 2014 - PR Newswire - PRF
Gilead Announces $5 Billion Share Repurchase Program 5:17 p.m. May 7, 2014 - BusinessWire - BZX
Medivir: a Supplemental New Drug Application Has Been Submitted to the U.S. FDA for Simeprevir in Combination with Sofosbuvir 8:06 a.m. May 7, 2014 - BusinessWire - BZX
Biotech Stocks Review -- Research on Retrophin, Merrimack, Gilead Sciences, and Rexahn Pharma 12:37 p.m. May 6, 2014 - PR Newswire - PRF
BetterInvesting Magazine Releases July Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use 4:15 p.m. May 2, 2014 - PR Newswire - PRF
Parion Sciences Reacquires Rights to Epithelial Sodium Channel Inhibitors 9:00 a.m. April 30, 2014 - PR Newswire - PRF
The World Market for Orphan Drugs 6:59 p.m. April 29, 2014 - PR Newswire - PRF
Critical Alerts For Comcast, Gilead Sciences, Ciena, Adobe Systems, and Celldex Therapeutics Released By InvestorsObserver 9:31 a.m. April 29, 2014 - PR Newswire - PRF
Federal Circuit Rules for Axinn Client Natco Pharma Ltd. in Tamiflu Patent Appeal 1:50 p.m. April 25, 2014 - BusinessWire - BZX
Stockholder Rights Plan, Quarterly Results, Clinical Trial Results, Purchase Agreements, and New Contracts - Analyst Notes on Allergan, Gilead, Pfizer, Actavis and Express Scripts 8:00 a.m. April 25, 2014 - PR Newswire - PRF
Gilead Sciences Announces First Quarter 2014 Financial Results 4:03 p.m. April 22, 2014 - BusinessWire - BZX
Gilead Sciences’ New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA 4:30 p.m. April 21, 2014 - BusinessWire - BZX
Young Scientists From Around the State Will Compete for Top Honors at the 63rd California State Science Fair 6:31 p.m. April 16, 2014 - PR Newswire - PRF
Gilead Sciences to Release First Quarter 2014 Financial Results on Tuesday, April 22, 2014 5:00 p.m. April 15, 2014 - BusinessWire - BZX
(0)
(0)Scroll down for more posts ▼